

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JBM (HEALTHCARE) LIMITED

健倍苗苗(保健)有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2161)

PROFIT WARNING AND INSIDE INFORMATION

This announcement is made by JBM (Healthcare) Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform shareholders of the Company (the “**Shareholders**”) and potential investors that, based on its preliminary assessment of the unaudited consolidated management accounts of the Group and information currently available to the Board, the Group’s profit attributable to equity shareholders of the Company for the six months ended 30 September 2021 (the “**Review Period**”) is expected to decrease by more than 50% as compared to that of approximately HK\$21,650,000 for the corresponding period in 2020 (the “**Previous Period**”). This decrease was mainly attributable to the sluggish consumer demand in both domestic and certain overseas markets caused by the COVID-19 pandemic. The lingering travel restrictions across the region have had a negative impact on the sales and selling prices of certain products of the Group. Furthermore, there was an one-off pandemic relief subsidy in the amount of approximately HK\$6.3 million from the government of the Hong Kong Special Administrative Region (the “**Hong Kong Government**”) during the Previous Period. There was no such a subsidy from the Hong Kong Government during the Review Period. In the midst of such a challenging market sentiment, the Company spared no efforts in realising business opportunities in the market. During the Review Period, the Group has launched a number of new products in the health and wellness sector and is making sound progress on the cross border e-commerce platform. Going forward, the Group will continue to optimise its resources in realising the growth strategies whilst pragmatically striving for cost savings through cost control initiatives.

The information contained in this announcement represents a preliminary assessment by the Board with reference to the unaudited consolidated management accounts of the Group and other information available to the Board. Such information has not yet been reviewed by the auditor or the audit committee of the Board. As the Company is still in the process of finalising its interim financial results for the Review Period (the “**Interim Results**”), the Interim Results may be different from the information set out in this announcement. Further details of the Interim Results will be included in the Company’s Interim Results announcement, which is expected to be published in late November 2021.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
JBM (Healthcare) Limited
Wong Yat Wai, Patrick
Executive Director and Chief Executive Officer

Hong Kong, 5 November 2021

As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek as the Chairman and non-executive Director, Mr. Wong Yat Wai, Patrick (also as Chief Executive Officer) and Dr. Chu Ka Wing as executive Directors, Mr. Yim Chun Leung and Mr. Yeung Kwok Chun, Harry as non-executive Directors, and Mr. Chan Kam Chiu, Simon, Mr. Luk Ting Lung, Alan and Mr. Lau Shut Lee, Tony as independent non-executive Directors.